News

InBio and Beckman Coulter Partner to Advance Food Allergy Diagnostics

InBio, a global leader in high-quality, purified allergen proteins, and Beckman Coulter Life Sciences, a Danaher company and a global leader in laboratory automation and innovation, are collaborating to enhance the performance of basophil activation tests (BAT) for food allergy research. The collaboration integrates InBio’s Food Protein Standards and purified allergens with the Next-Generation Basophil Activation Test (BAT) platform from Beckman Coulter Life Sciences.

InBio’s Food Protein Standards and purified allergen components are potent, biologically active proteins derived from foods such as peanut, egg, milk, tree nuts, and shellfish. These reagents are a critical component for BAT tests, and are validated for immunological consistency, ensuring reproducibility in high-sensitivity assays.

The Next-Generation BAT* by Beckman Coulter Life Sciences is a research use only breakthrough in functional allergy testing that offers researchers a powerful tool to assess allergic sensitization and reactivity with greater precision. Leveraging advanced flow cytometry and automation to measure basophil activation in response to allergen exposure, the Next-Generation BAT is an in vitro alternative to oral food challenges. The integration of InBio’s food proteins ensures consistency in allergen stimulation, reducing variability and improving test interpretation.

The Next-Generation BAT powered by InBio allergens can test for multiple allergens at once through a blood draw — saving hours of food testing and exposure to potentially harmful reactions.

Read more here.

Recent News

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza